Effects of BW245C, a prostaglandin dp receptor agonist, on systemic and regional haemodynamics in the anaesthetized rat

1. Prostaglandin D (DP) receptor agonists have been shown to induce hypotension in rat models, possibly via peripheral vasodilation. However, it is not known which tissues and organs are most responsive.

[1]  D. W. Gray,et al.  Functional pharmacology of human prostanoid EP2 and EP4 receptors. , 2004, European journal of pharmacology.

[2]  J. Sullivan,et al.  Emerging Pharmacologic Approaches for the Treatment of Lower Urinary Tract Disorders , 2004, Journal of Pharmacology and Experimental Therapeutics.

[3]  M. Watkins,et al.  Expression of functional prostaglandin D (DP) receptors in human corpus cavernosum smooth muscle , 2002, International Journal of Impotence Research.

[4]  J. Fouron,et al.  Prostanoid receptors: ontogeny and implications in vascular physiology. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  S. Narumiya,et al.  Prostaglandin D2 as a mediator of allergic asthma. , 2000, Science.

[6]  Y. Boie,et al.  The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. , 2000, Biochimica et biophysica acta.

[7]  A. Ford-hutchinson,et al.  A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. , 1999, European journal of pharmacology.

[8]  A. Quintana,et al.  Effects of intravenous administration of prostacyclin on regional blood circulation in awake rats , 1999, British journal of pharmacology.

[9]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[10]  Y. Boie,et al.  Molecular Cloning and Characterization of the Human Prostanoid DP Receptor (*) , 1995, The Journal of Biological Chemistry.

[11]  S. Narumiya,et al.  Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  E. Epstein.  The anomaly of silicon in plant biology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Whittle,et al.  Antagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C , 1989, British journal of pharmacology.

[14]  A. Webster,et al.  Effects of single oral dose administration of a hydantoin prostaglandin analogue BW 245C in man. , 1984, Life sciences.

[15]  J. Vane,et al.  Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue. , 1983, Prostaglandins.

[16]  J I Hoffman,et al.  Blood flow measurements with radionuclide-labeled particles. , 1977, Progress in cardiovascular diseases.

[17]  J. Vane,et al.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.

[18]  W. Shen,et al.  Vasovagal syncope. , 2000, Annals of internal medicine.

[19]  J. O'grady,et al.  Effect of a hydantoin prostaglandin analogue, BW245C, during oral dosing in man. , 1985, Prostaglandins.

[20]  J. Casals-stenzel,et al.  Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. , 1983, Prostaglandins.